Search bioRxiv⌕ Search

Biology subjects

Espinosa-Carrasco, G.

Publications and source records attributed to Espinosa-Carrasco, G..

3 recordsLinked to original sources

Differentiation of naive into memory-phenotype CD8+ T cells does not promote the breakdown of peripheral tolerance in irradiated mice

Lymphodepletion, which is currently used as adjuvant for adoptive cytotoxic T cell immunotherapy in cancer, promotes the breakdown of peripheral CD8+ T cell tolerance. Under lymphopenic conditions, naive T cells proliferate due to a greater availability of homeostatic cues. Proliferating CD8+ T cells acquire a phenotype and functionality that is similar to memory cells and are termed memory-like cells. Since memory cells are thought to have a lower activation threshold than naive cells, it has been proposed that differentiation of potentially autoreactive CD8+ T cells into memory-like cells could drive the breakdown of tolerance under lymphopenic conditions. Here we studied whether lymphopenia induced proliferation and differentiation are required to overcome CD8+ T cell cross-tolerance in irradiated mice. Surprisingly, we found that blocking homeostatic proliferation by IL-7 neutralization did not prevent self-reactivity. CD8+ T cells that remained in a naive state still became effectors upon antigen cross-presentation as efficiently as memory-like cells. Nonetheless, lymphopenia induced proliferation did enhance CD8+ T cell mediated self-reactivity at low T cell frequencies by increasing autoreactive T cell numbers. Thus, although homeostatic proliferation enhances CD8+ T cell anti-self responses, differentiation into memory-like cells is not essential for the breakdown of cross-tolerance after irradiation.

immunology↗

Intratumoral immune triads are required for adoptive T cell therapy-mediated elimination of solid tumors

Tumor-reactive CD8 T cells found in cancer patients are frequently dysfunctional, unable to halt tumor growth. Adoptive T cell transfer (ACT), the administration of large numbers of in vitro-generated cytolytic tumor-reactive CD8 T cells, is an important cancer immune therapy being pursued. However, a limitation of ACT is that transferred CD8 T cells often rapidly lose effector function, and despite exciting results in certain malignancies, few ACT clinical trials have shown responses in solid tumors. Here, we developed preclinical cancer mouse models to investigate if and how tumor-specific CD4 T cells can be enlisted to overcome CD8 T cell dysfunction in the setting of ACT. In situ confocal microscopy of color-coded cancer cells, tumor-specific CD8 and CD4 T cells, and antigen presenting cells (APC), combined with functional studies, revealed that the spatial positioning and interactions of CD8 and CD4 T cells, but not their numbers, dictates ACT efficacy and anti-tumor responses. We uncover a new role of antigen-specific CD4 T cells in addition to the known requirement for CD4 T cells during priming/activation of naive CD8 T cells. CD4 T cells must co-engage with CD8 T cells and APC cross-presenting CD8-and CD4-tumor antigens during the effector phase, forming a three-cell-cluster (triad), to license CD8 T cell cytotoxicity and mediate cancer cell elimination. Triad formation transcriptionally and epigenetically reprogram CD8 T cells, prevent T cell dysfunction/exhaustion, and ultimately lead to the elimination of large established tumors and confer long-term protection from recurrence. When intratumoral triad formation was disrupted, adoptively transferred CD8 T cells could not be reprogrammed, and tumors progressed despite equal numbers of tumor-infiltrating CD8 and CD4 T cells. Strikingly, the formation of CD4 T cell::CD8 T cell::APC triads in tumors of patients with lung cancers treated with immune checkpoint blockade was associated with clinical responses, but not CD4::APC dyads or overall numbers of CD8 or CD4 T cells, demonstrating the importance of triads in non-ACT settings in humans. Our work uncovers intratumoral triads as a key requirement for anti-tumor immunity and a new role for CD4 T cells in CD8 T cell cytotoxicity and cancer cell eradication.

immunology↗

Integrin beta1 optimizes diabetogenic T cell migration and function in the pancreas

T cell search behavior is dictated by their need to encounter their specific antigen to eliminate target cells. However, mechanisms controlling effector T cell motility are highly tissue-dependent. Specifically, how diabetogenic T cells encounter their target beta cells in dispersed islets throughout the pancreas during autoimmune diabetes remains unclear. Using intra-vital 2-photon microscopy in a mouse model of diabetes, we found that CXCR3 chemokine downregulated CD8+ T cell motility specifically within islets, promoting effector cell confinement to their target sites. In contrast, T cell velocity and directionality in the exocrine tissue were enhanced along blood vessels and extra-cellular matrix fibers. This guided migration implicated integrin-dependent interactions, since integrin blockade impaired exocrine T cell motility. In addition, integrin {beta}1 blockade decreased CD4+ T cell effector phenotype specifically in the pancreas. Thus, we unveil an important role for integrins in the pancreas during autoimmune diabetes that may have important implications for the design of new therapies.

immunology↗